- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2011 (2011), Article ID 726723, 13 pages
Traditional Chinese Medicines in Treatment of Patients with Type 2 Diabetes Mellitus
1Life Science Division, Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, China
2Laboratory of Pathological Sciences, Basic Medical College, Nanjing University of Traditional Chinese Medicine, Nanjing 210029, China
Received 11 August 2010; Revised 16 December 2010; Accepted 19 January 2011
Copyright © 2011 Weidong Xie et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Type 2 diabetes mellitus (T2DM) occurs in 95% of the diabetic populations. Management of T2DM is a challenge. Traditional Chinese medicines (TCM) are usually served as adjuvants used to improve diabetic syndromes in combination of routine antidiabetic drugs. For single-herb prescriptions, Ginseng, Bitter melon, Golden Thread, Fenugreek, Garlic, and Cinnamon might have antidiabetic effects in T2DM patients. Among 30 antidiabetic formulas approved by the State Food and Drugs Administrator of China, top 10 of the most frequently prescribed herbs are Membranous Milkvetch Root, Rehmannia Root, Mongolian Snakegourd Root, Ginseng, Chinese Magnoliavine Fruit, Kudzuvine Root, Dwarf Lilyturf Tuber, Common Anemarrhena Rhizome, Barbary Wolfberry Fruit, and India Bread, which mainly guided by the theory of TCM. Their action mechanisms are related to improve insulin sensitivity, stimulate insulin secretion, protect pancreatic islets, and even inhibit intake of intestinal carbohydrates. However, it is very difficult to determine antihyperglycemic components of TCM. Nevertheless, TCM are becoming popular complementary and alternative medicine in treatment of syndromes of T2DM. In the future, it requires further validation of phytochemical, pharmacological, and clinical natures of TCM in T2DM in the future studies, especially for those herbs with a high prescription frequency.
Diabetes mellitus is associated with the increase in cardiovascular diseases and other complications [1–4]. There is increasing incidence of the disease. Type 2 diabetes mellitus (T2DM) occurs in 95% of the diabetic populations. Management of T2DM is a challenge. Plants play an important role in introducing new medicines with antidiabetic activities, such as antidiabetic drugs, biguanidines derives from guanidine of French lilac (Galega officinalis). Traditional and modern Chinese medicines are becoming the important sources for the development of antidiabetic drugs [5–10]. There is an increasing need for those T2DM patients intolerant of adverse effects of chemical drugs and/or those who cannot afford expensive medical expenditures in developing countries.
There are some original or review papers on herbal medicines in treatment of T2DM [5–7]. They supply some useful information of sources, active principles, phytochemistry, and pharmacology of traditional Chinese medicines (TCM) with antidiabetic activities. However, there is still insufficient evidence to draw definitive conclusions about the efficacy of TCM for diabetes. Li et al. systemically list many TCM with antidiabetic effects but have not showed those antidiabetic formula products which are mainstay of TCM . Liu et al. indicate some TCM including single herb prescriptions and formula in treatment of T2DM but most of these herb medicines do not belong to regular products of TCM approved to be used clinically . Though Jia et al. have reviewed the antidiabetic herbal drugs officially approved in China  but show only eight antidiabetic herbal formulas, it is not enough to display special aspects of TCM.
In this paper, we updated and supplemented some reputed TCM approved by the State Food and Drugs Administrator (SFDA) in China mainland in the treatment of T2DM and tried to supply some worthy herb sources and conduct a discussion on how to develop TCM in treatment of T2DM.
We searched for papers published in MEDLINE, CNKI, EMBASE, Wiley InterScience, Elselvier databases without language limit by retrieving key words “herb/plant, clinic/clinical, human/patients, type 2 diabetes mellitus” to identify herb medicines in treatment of type 2 diabetes; only those paper with clinical trials will be selected. For Chinese herb formulas, only those listed in the database of products with antidiabetic effect in the official website of http://www.sfda.gov.cn/ will be retrieved. These searches were conducted by two independent examiners. The last date of the search was December 1, 2010.
3.1. Single-Herb Prescriptions
There were only a few reputed single-herb prescriptions found in China. Although those single herb prescriptions had reputed records or/and promising clinical results, they still served as adjuncts or supplements for T2DM patients.
Ginseng together with its roots, stalk, leaves, and berries had significant antihyperglycemic effect in many animal models of T2DM. Some clinical studies indicated that Ginseng is an emerging alternative therapy for T2DM [11–13]. Ginseng significantly decreased insulin resistance and fasting blood glucose (FBG) in T2DM patients [14, 15]. In china, among 30 cases of T2DM treated with Renshen tangtai, an injection contained Ginseng polypeptide and polysaccharides; 86.7% of the patients showed appreciable effect on diabetic symptoms . However, Ginseng had no effect on indices of glucose regulation following acute or chronic ingestion in healthy volunteers . Its active compounds with antihyperglycemic effects included ginsenosides, polypeptide , and polysaccharides . Ginseng might exert a antihyperglycemic effect by promoting insulin secretion , protecting pancreatic islets , stimulating glucose uptake , and enhancing insulin sensitivity . Future studies require identifying the component(s) of Ginseng . Ginseng had no significant side effects . However, chronic overdosed administration of Ginseng may suffer from gastrointestinal, mental, cardiovascular, and hormone disorders. Children and pregnant women should be cautious of using this herb.
3.3. Golden Thread
Golden Thread is commonly used to treat diabetes in China. Berberine is an isoquinoline alkaloids and the active ingredient of Golden Thread. Berberine had a significant antihyperglycemic effect in both 36 patients newly diagnosed with T2DM and also in 48 poorly controlled patients with T2DM . This effect was comparable to metformin. Berberine increased glucose uptake and stimulates glycolysis by activation of AMP-activated protein kinase (AMPK) [24, 25]. In addition, berberine promoted insulin secretion by modulating glucagon-like peptide-1 release . Berberine promoted beta cell regeneration . In intestinal region, berberine inhibited glucose absorption by suppressing disaccharidase activities . Expect for transient gastrointestinal adverse effects, no significant functional liver or kidney damages were documented.
3.4. Bitter Melon
Bitter melon is more commonly used by persons from Asian countries. Bitter melon lowered fasting and postprandial serum glucose levels in T2DM patients . Although bitter melon might have antihyperglycemic effects, data were not sufficient to recommend its use in the absence of careful supervision and monitoring . Major active compounds in this plant contained cucurbitane triterpenoids , polypeptide-p, charantin, and vicine . Bitter melon exerted a antihyperglycemic effect by inhibition of protein tyrosine phosphatase 1B (PTP1B), activation of AMPK, increase of glucose transporter type 4 (GLUT4) expression, promotion of the recovery of beta cells , and insulin-mimicking action . However, adverse effects of bitter melon included hypoglycemic coma and convulsions in children and headaches . Bitter melon might have additive effects when taken with other glucose-lowering agents. Despite this, no serious adverse effects were reported in all the clinical trials. There were no documentations of death from any cause, morbidity, (health-related) quality of life, and costs .
Fenugreek improved blood glucose control and insulin resistance in diabetic patients [37–39]. The findings of 18 cases of patients showed that FBG, triglycerides, and very low-density lipoprotein cholesterol (VLDL-C) decreased significantly after taking fenugreek seed soaked in hot water . Combined therapy of total saponins of Fenugreek with sulfonylureas hypoglycemic drug lowered the blood glucose level and ameliorated clinical symptoms in 46 cases of T2DM compared with 23 cases of controls . Active components of Fenugreek included trigonelline, nicotinic acid, GII , diosgenin , 4-hydroxyisoleucine , total saponins , Fenugreek oil , and soluble dietary fibre fraction . Its antihyperglycemic mechanisms were associated with potentiating insulin secretion, increasing insulin sensitivity , and inhibiting intestinal carbohydrate digestion and absorption . Fenugreek was relatively safe  and also had no genotoxicity . However, we should be cautious of its use combined with aspirin in case of the risk of bleeding .
Garlic had antihyperglycemic and antihyperlipidemic effects in T2DM patients [51, 52]. In the 4-week double-blinded placebo-controlled study in 60 T2DM patients, Garlic lowered FBG, serum fructosamine, and serum triglyceride levels . Garlic constituents mainly included sulfur-containing compounds (e.g., diallyl trisulfide , ajoene , S-allyl cysteine sulfoxide ) and garlic oil. Garlic improved glycemic control through increased insulin secretion and enhanced insulin sensitivity . Garlic had no significant adverse effects. However, we should be cautious of excess and chronic administration of garlic because of gastrointestinal troubles. If patients suffered from hepatitis, kidney and heart diseases, intake of garlic should be prohibited .
The oral administration of cinnamon per day reduced serum glucose and lipid levels in patients with T2DM, suggesting that the inclusion of cinnamon in the diet of patients with T2DM would reduce risk factors associated with diabetes and cardiovascular diseases . Cinnamon lowered hemoglobin A1c (HbA1C) by 0.83% compared with usual care alone lowering HbA1C by 0.37% in patients with T2DM in a randomized, controlled trial . Its active components contained cinnamaldehyde  and naphthalenemethyl ester derivative . Its antihyperglycemic effects were worked by promoting insulin release, enhancing insulin sensitivity, and increasing glucose disposal. Also, Cinnamon seemed to exert insulin-like effects through regulation of PTP1B and insulin receptor kinase . Cinnamon had no significant adverse effects but may be of concern when used in excessive amounts .
3.8. Traditional Chinese Formulas
In this paper, we listed 30 traditional Chinese herbal formulas approved by China SFDA (Table 1). Although these formulas are listed in China SFDA website, we had no authorized access to their unpublished clinical data. Only part of them is published in the open journals but mostly in Chinese journals. Most of these Chinese formulas were used in combination with routine compounds such as glibenclamide or metformin and indicate that they had better effects in lowering blood glucose and improving diabetic symptoms than routine drugs alone in T2DM patients. In two Chinese formulas, glibenclamide was directly added and considered as a component of formulas. A very small amount of Chinese formulas were used as monotherapy in slight or mild cases of T2DM.
Among 30 formulas above, we listed 3 or more than 3 frequently prescribed herbs in Figure 1. Top 10 of the most frequently prescribed herbs were Membranous Milkvetch Root, Rehmannia Root, Mongolian Snakegourd Root, Ginseng, Chinese Magnoliavine Fruit, Kudzuvine Root, Dwarf Lilyturf Tuber, Common Anemarrhena Rhizome, Barbary Wolfberry Fruit, and India Bread. According to the theory of TCM, these herbs could be grouped as Qi (energy-) invigorating, Yin (body fluids-) nourishing, heat (body heat-) clearing and stasis-reducing (improving blood circulation and kidney function) drugs (Table 2). For Qi-invigorating drugs, the most frequently prescribed herb was Membranous Milkvetch Root (Huang qi, 23 in 30). For Yin-nourishing drugs, the most frequently prescribed herb was Mongolian Rehmannia Root (Di huang, 22 in 30). For heat-clearing drugs, the most frequently prescribed herb was Common Anemarrhena Rhizome (Zhi mu, 12 in 30). For stasis-reducing drugs, the most frequently prescribed herb was India Bread (Fu ling, 10 in 30)
3.9. Yuquan Wan
Yuquan Wan (YQW) has been long used to treat diabetes in Chinese medicines. Among 18 diabetic patients treated with Yuquan Wan for 1 month , 72% cases showed significant or moderate improvement in fasting blood glucose and other diabetic symptoms such as thirst and hunger disappeared. In relation to diabetic complications, Yuquan Wan improved the index of kidney injures of early diabetic nephropathy in diabetic patients, which suggested that it would prolong the development of diabetic nephropathy . YQW improved the insulin resistance  in patients with T2DM. YQW reduced the levels of the increased proinflammatory cytokines in patients with T2DM . YQW had a significant effect on the pharmacokinetics of metformin hydrochloride in diabetic rats . This might explain why YQW had a better effect than metformin alone. Taken together, YQW mainly improved diabetic complications and exerted a antihyperglycemic effect mediated likely by enhancing insulin sensitivity. No significant adverse effects were reported of YQW.
3.10. Tangmaikang Jiaonang
Tangmaikang Jiaonang (TMK) is used to treat T2DM and its complications. There were many clinical reports of TMK with good effects in treatment of T2DM [69, 70], insulin resistance [71, 72], dyslipidemia , diabetic peripheral neuropathy, and blood fluid parameters [69, 74]. These results were drawn only by comparing between before and after combined treatment with routine antidiabetic drugs such as sulfonylureas or biguanides. One clinical report showed that TMK had a better effect in treatment of T2DM patients than Xiaoke Wan . TMK could treat T2DM and could reduce hypoglycemia and the dose of insulin at the base of controlled blood glucose . TMK combined with metformin had better effect than metformin alone in newly diagnosed T2DM patients . TMK enhanced the effect of routine drug on diabetic peripheral neuropathy . TMK combined with routine drugs had more improvement in blood fluid parameters than routine drugs alone . TMK mainly improved diabetic complications and exerted an antihyperglycemic effect mediated by increasing insulin sensitivity but mostly used in combination with the regular antihyperglycemic measurements. There were no significant adverse effects reported in the previous studies.
3.11. Xiaoke Wan
Xiaoke Wan (XKW) contains several herb medicines and a western compound, glibenclamide. It is used to treat T2DM. Many clinical reports showed that XKW had similar or better antihyperglycemic effects in diabetic patients compared with glibenclamide [80–84]. In these reports, about 82% , 94.1% , 92% , 93.8 , and 98%  of T2DM patients had significant or moderate improvement in hyperglycemia and other diabetic symptoms, respectively. XKW had more improvement in other diabetic symptoms such as thirsty and hungry or complications such as blood lipid and blood fluid parameters than glibenclamide. Besides of stimulation of insulin secretion mediated by glibenclamide (one of components in XKW), XKW enhanced insulin sensitivity likely mediated by promoting adiponectin secretion in T2DM patients . Although XKW was claimed to be more safe than glibenclamide to a certain extent, herb medicine components cannot completely resist the untoward effect of glibenclamide. To be particular, overuse should be avoided this formula contained glibenclamide which easily cause because severe hypoglycemic response after overuse. Indeed, it had a severe hypoglycemic response in 36 cases of T2DM patients .
3.12. Jinqi Jiangtang Pian
Jinqi Jiangtang Pian (JQJT) had a moderate antihyperglycemic effect in mild or moderate T2DM patients but had no significant effect in severe T2DM patients when it was used alone . Nevertheless, its use combined with positive drug such as glibenclamide had better effects in T2DM patients after the treatment than glibenclamide alone , even when those positive drugs could not work well in those patients . In addition, JQJT combined with positive drugs (such as metformin, Acarbose or glibenclamide) might have more improvement in diabetic dyslipidemia  and the early development of diabetic nephropathy  than positive drugs alone. The effect of JQJT was confirmed in 30 cases of T2DM recently once more . In addition, effective interventions of JQJT on prediabetes were conducting  since prediabetes was a growing health concern where a large percentage of these patients develop full T2DM. Its antihyperglycemic action was related to improvement of insulin sensitivity by comprehensive mechanisms, for example, reducing serum lipid, regulating immune functions, enhancing antioxidative systems, and improving micro-circulation and beta-cell function . JQJT had no significant adverse effects in T2DM patients.
3.13. Jiangtangjia Pian and Kelening Jiaonang
Jiangtangjia Pian (JTJ) is used to treat T2DM patients. Among 48 cases of T2DM patients, JTJ improved blood glucose control after the treatment combined with antidiabetic drugs such as sulfonylureas, biguanides, and insulin . Interestingly, in this study, blood glucose was poor controlled in these patients of T2DM by using those antidiabetic drugs before the use of JTJ. Furthermore, its single use also had antihyperglycemic effect in 10 newly diagnosed T2DM patients. Herbs in Kelening Jiaonang (KLL) were similar to Jiangtangjia Pian but might have different oral dosage or prepared process. This formula was used to treat T2DM patients. In clinical report, KLL significantly lowered blood glucose level in T2DM patients combined with regular antidiabetic drugs after treatment compared with that before treatment . Glibenclamide in combination with KLL in treatment of T2DM patients was more effective and less toxic than its single use . KLL for 1 month of oral administration significantly improved blood glucose levels in 30 cases of T2DM patients who administrated regular antidiabetic drugs but had poor control . Also, 8 weeks of treatment of KLL had a significant improvement in blood glucose in those T2DM patients with sulfanylurea failure, which indicated that KLL might improve insulin resistance . Both JTJ and KLL reduced the blood glucose and increased body weight in alloxan-induced diabetic mice [99, 100], suggesting that these drugs might exert an insulin-like effects. No significant adverse effects were reported of these herbs.
3.14. Xiaotangling Jiaonang
Xiaotangling Jiaonang (XTL) is another formula contained both herb medicines and glibenclamide. It was reported that XTL had significant antihyperglycemic effect in 30 cases of T2DM after treatment compared with that before treatment . Among 44 cases of T2DM, 88.6% of patients showed significant and moderate improvement after XTL treatment while 75.0% of those patients (n = 32) treated with positive control showed the effect . About 98.67% of T2DM patients (n = 150) treated with XTL in combination with metformin showed significant or moderate improvement in diabetic symptoms and other compications (diabetic dyslipidemia and blood fluid parameters) while only 78% of those patients (n = 50) treated with metformin showed similar effects . In addition, management of XTL effectively improved blood glucose control in 66.7% of diabetic patients (n = 24) with secondary failure of sulfanylurea ; XTL treatment also increased insulin sensitivity index in T2DM patients (n = 47) compared with glibenclamide (n = 35), which indicated that treatment of XTL could improve insulin resistance in T2DM patients. Antihyperglycemic mechanisms of XTL are related to improve insulin sensitivity in T2DM patients. We should be cautious of their hypoglycemic events since XTL contained glibenclamide as XKW did.
3.15. Shenqi Jiangtang Keli
Shenqi Jiangtang Keli (SQJT) is clinically used in T2DM patients. In a clinical study, 82.85% of T2DM patients (n = 35) show appreciable effects after SQJT treatment . SQJT significantly enhanced the antihyperglycemic effect of metformin in 30 cases of T2DM patients . SQJT alone had significant antidiabetic effect in 235 cases of T2DM patients compared with diet or exercise-controlled controls. But most of patients were diagnosed as slight or mild cases . SQJT mainly improved the diabetic syndromes and even exerted a antihyperglycemic effect in T2DM patients with secondary-failure to sulfonylureas . Antidiabetic mechanisms of SQJT are related to improve insensitivity  and restore functions of pancreatic islets in T2DM patients . SQJT had no significant adverse effects.
3.16. Other TCM
3.16.1. Yangyin Jiangtang Pian
In a clinical study , 95.8% of T2DM patients (n = 120) treated with Yangyin Jiangtang Pian (YYJT) in combination with metformin showed a significant and moderate improvement in diabetic symptoms while this effect was done only in 72.5% of the patients treated with metformin (n = 40). YYJT lowered blood glucose, increased insulin levels, enhanced insulin sensitivity, and improved blood fluid parameters in alloxan-induced diabetic rats . No significant adverse effects were documented of YYJT.
3.16.2. Xiaoke Jiangtang Pian
Xiaoke Jiangtang Pian (XKJT) had significant antihyperglycemic in T2DM patients (70% of 30 cases show appreciable effect) . XKJT also showed a significant glucose-lowering effect in alloxan-reduced mice. In acute and subacute toxicological trials, no significant adverse effects were observed in rats or dogs.
3.16.3. Yijin Jiangtang Jiaonang
Among 42 cases of T2DM patients treated with Yijin Jiangtang Jiaonang (YJJT), about 78.6%, 83.3%, and 45.2% of patients showed appreciable decrease in fasting blood glucose, postprandial blood glucose, and HbA1c levels, respectively . In addition, YJJT had significant decrease in blood triglycerides and total cholesterol levels. YJJT might exert antidiabetic activities through enhancing insulin sensitivity. No hypoglycemic events or any significant adverse effect was recorded.
4. Discussion and Perspective
4.1. The Theory of TCM Plays a Fundamental Role in Prescribing TCM in Treatment of T2DM Patients
In this review, for single-herb prescriptions, Ginseng, Bitter melon, Golden Thread, Fenugreek, Garlic, and Cinnamon might have antidiabetic effects in T2DM patients. Among 30 antidiabetic formulas approved by China SFDA, top 10 of the most frequently prescribed herbs are Membranous Milkvetch Root, Rehmannia Root, Mongolian Snakegourd Root, Ginseng, Chinese Magnoliavine Fruit, Kudzuvine Root, Dwarf Lilyturf Tuber, Common Anemarrhena Rhizome, Barbary Wolfberry Fruit, India Bread, which mainly guided by the theory of TCM. In spite of diversity of Chinese formulas, some herb components are frequently presented in formulas. Based on the theory of TCM, most of these Chinese herbs investigated can be grouped as Qi (energy)-invigorating, Yin (body fluids)-nourishing, Heat (body heat)-clearing, and Stasis (congested blood circulation or urine)-reducing drugs, and so forth. Diabetes (named Xiaoke in the theory of TCM) is usually associated with the deficiency of both Qi (energy) and Yin (body fluids) and results in the Heat of tissues and blood or urine Stasis (congested blood circulation or urine) . This may show the syndromes of Shang Xiao (impairment of the body fluid by the lung-heat), Zhong Xiao (excessive blazing heat in the stomach), and Xia xiao (deficiency of the kidney-Yin, deficiency of both Yin and Yang) in TCM. Those prescribed herbs might be effective to treat the diabetic syndromes in TCM. Although the theory of TCM is difficult to understand, it is very useful to direct us to develop effective traditional Chinese herbs with systemic antidiabetic activities. Figure 2 indicates the action model of TCM in treatment of T2DM patients. Indeed, the rich and colorful TCM may be prescribed according to the diversity of diabetic syndromes or complications, which is similar to personalized therapy in western medicine . In the future, we might select these highly frequently prescribed herbs as further study in order to disclose their scientific nature.
4.2. TCM Serve As Effective Complementary and Alternative Medicine in Treatment of T2DM Patients
As described above, TCM serve as effective complementary and alternative medicine in treatment of T2DM patients although part of results is acquired by poor designs or controls. Most of TCM showed promising results on antidiabetic effects in combination with routine antidiabetic treatment. A very small amount of TCM could alone get satisfied antidiabetic effects in those T2DM patients newly diagnosed or with the failure of routine antidiabetic treatments. In addition, most of TCM are lower cost, more effective for some specific complications, and less adverse effect than regular antihyperglycemic drugs. This may also be the reasons why TCM are popular as complementary and alternative medicine in treatment of syndromes of T2DM. Action mechanisms of TCM mainly involved in improving insulin sensitivity, stimulating insulin secretion, protecting pancreatic islets, inhibiting intake of intestinal carbohydrates, and so on. These actions may play an important role in serving as effective complementary and alternative medicines to routine antidiabetic drugs.
Taken together, TCM, especially for those herbs with a high prescription frequency, are hopeful to serve as effective complementary and alternative medicine in treatment of T2DM patients based on the theory of TCM. However, active components of TCM are still far from our knowledge since TCM are usually consisted of more than 2 herbs and each herb contains hundreds of compounds. We should establish some appropriate methods to define the active components of TCM and to guarantee stable pharmacological and clinical effects. On the other hand, pharmacological or clinical effects of TCM should be further validated in future studies since part of results is acquired by poor designs or controls.
This study was supported by the National Natural Science Foundation of China (81072680), the Natural Science foundation of Guangdong Province (10151805702000002), The Specialized Research Fund for the Doctoral Program of Higher Education of China (20100002120017), and the Tertiary College Science Foundation of Nanshan, Shenzhen (2008028).
- Y. S. Ali, M. F. Linton, and S. Fazio, “Targeting cardiovascular risk in patients with diabetes: management of dyslipidemia,” Current Opinion in Endocrinology, Diabetes and Obesity, vol. 15, no. 2, pp. 142–146, 2008.
- W. Xie, D. Xing, Y. Zhao et al., “A new tactic to treat postprandial hyperlipidemia in diabetic rats with gastroparesis by improving gastrointestinal transit,” European Journal of Pharmacology, vol. 510, no. 1-2, pp. 113–120, 2005.
- W. Xie and L. Du, “High-cholesterol diets impair short-term retention of memory in alloxan-induced diabetic mice, but not acquisition of memory nor retention of memory in prediabetic mice,” Life Sciences, vol. 77, no. 5, pp. 481–495, 2005.
- W. D. Xie, Y. Nie, L. J. Du, Y. O. Zhang, and G. P. Cai, “Preventive effects of fenofibrate and vitamin C on the development of type 2 diabetes and its complications in NIH mice induced by small-dose streptozotocin and lard,” Pharmacological Research, vol. 55, pp. 392–399, 2007.
- W. Jia, W. Gaoz, and L. Tang, “Antidiabetic herbal drugs officially approved in China,” Phytotherapy Research, vol. 17, no. 10, pp. 1127–1134, 2003.
- W. L. Li, H. C. Zheng, J. Bukuru, and N. De Kimpe, “Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus,” Journal of Ethnopharmacology, vol. 92, no. 1, pp. 1–21, 2004.
- J. P. Liu, M. Zhang, W. Y. Wang, and S. Grimsgaard, “Chinese herbal medicines for type 2 diabetes mellitus,” Cochrane Database of Systematic Reviews, no. 3, article CD003642, 2004.
- W. Xie, D. Xing, H. Sun, W. Wang, Y. Ding, and L. Du, “The effects of Ananas comosus L. leaves on diabetic-dyslipidemic rats induced by alloxan and a high-fat/high-cholesterol diet,” American Journal of Chinese Medicine, vol. 33, no. 1, pp. 95–105, 2005.
- W. Xie, Y. Zhang, N. Wang et al., “Novel effects of macrostemonoside A, a compound from Allium macrostemon Bung, on hyperglycemia, hyperlipidemia, and visceral obesity in high-fat diet-fed C57BL/6 mice,” European Journal of Pharmacology, vol. 599, no. 1–3, pp. 159–165, 2008.
- W. D. Xie, Y. N. Zhao, L. J. Du, G. P. Cai, D. Y. Gu, and Y. O. Zhang, “Scorpion in combination with Gypsum: novel antidiabetic activities in streptozotocin-induced diabetic mice by up-regulating pancreatic PPARγ and PDX-1 expressions,” Evidence-Based Complementary and Alternative Medicine. In press.
- V. Vuksan, J. L. Sievenpiper, Z. Xu et al., “Konjac-mannan and American ginseng: emerging alternative therapies for type 2 diabetes mellitus,” Journal of the American College of Nutrition, vol. 20, no. 5, supplement, pp. 370S–380S, 2001.
- E. A. Sotaniemi, E. Haapakoski, and A. Rautio, “Ginseng therapy in non-insulin-dependent diabetic patients,” Diabetes Care, vol. 18, no. 10, pp. 1373–1375, 1995.
- V. Vuksan, J. L. Sievenpiper, V. Y. Y. Koo et al., “American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus,” Archives of Internal Medicine, vol. 160, no. 7, pp. 1009–1013, 2000.
- S. W. Ma, I. F. F. Benzie, T. T. W. Chu, B. S. P. Fok, B. Tomlinson, and L. A. H. Critchley, “Effect of Panax ginseng supplementation on biomarkers of glucose tolerance, antioxidant status and oxidative stress in type 2 diabetic subjects: results of a placebo-controlled human intervention trial,” Diabetes, Obesity and Metabolism, vol. 10, no. 11, pp. 1125–1127, 2008.
- V. Vuksan, M. K. Sung, J. L. Sievenpiper et al., “Korean red ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes: results of a randomized, double-blind, placebo-controlled study of efficacy and safety,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 18, no. 1, pp. 46–56, 2008.
- H. Y. Guo, H. Q. Cai, T. Wang, X. J. Zhang, and H. Shen, “Renshen tangtai injection in treatment of 30 cases of type 2 diabetes mellitus,” Jilin Da Xue Xue Bao, vol. 29, pp. 206–207, 2003 (Chinese).
- J. L. Reay, A. B. Scholey, A. Milne, J. Fenwick, and D. O. Kennedy, “Panax ginseng has no effect on indices of glucose regulation following acute or chronic ingestion in healthy volunteers,” British Journal of Nutrition, vol. 101, no. 11, pp. 1673–1678, 2009.
- B. X. Wang, M. Yang, Y. L. Jin, Z. Y. Cui, and Y. Wang, “Studies on the hypoglycemic effect of ginseng polypeptide,” Acta Pharmaceutica Sinica, vol. 25, no. 6, pp. 401–405, 1990 (Chinese).
- J. T. Xie, J. A. Wu, S. Mehendale, H. H. Aung, and C. S. Yuan, “Anti-hyperglycemic effect of the polysaccharides fraction from American ginseng berry extract in ob/ob mice,” Phytomedicine, vol. 11, no. 2-3, pp. 182–187, 2004.
- K. Kim, M. Park, and H. Y. Kim, “Ginsenoside Rg3 suppresses palmitate-induced apoptosis in MIN6N8 pancreatic β-cells,” Journal of Clinical Biochemistry and Nutrition, vol. 46, no. 1, pp. 30–35, 2010.
- W. Shang, Y. Yang, L. Zhou, B. Jiang, H. Jin, and M. Chen, “Ginsenoside Rb stimulates glucose uptake through insulin-like signaling pathway in 3T3-L1 adipocytes,” Journal of Endocrinology, vol. 198, no. 3, pp. 561–569, 2008.
- J. Z. Luo and L. Luo, “Ginseng on hyperglycemia: effects and mechanisms,” Evidence-Based Complementary and Alternative Medicine, vol. 6, pp. 423–427, 2009.
- J. Yin, H. Xing, and J. Ye, “Efficacy of berberine in patients with type 2 diabetes mellitus,” Metabolism, vol. 57, no. 5, pp. 712–717, 2008.
- C. Chen, Y. Zhang, and C. Huang, “Berberine inhibits PTP1B activity and mimics insulin action,” Biochemical and Biophysical Research Communications, vol. 397, no. 3, pp. 543–547, 2010.
- J. Yin, Z. Gao, D. Liu, Z. Liu, and J. Ye, “Berberine improves glucose metabolism through induction of glycolysis,” American Journal of Physiology, vol. 294, no. 1, pp. E148–E156, 2008.
- Y. Yu, L. Liu, X. Wang et al., “Modulation of glucagon-like peptide-1 release by berberine: in vivo and in vitro studies,” Biochemical Pharmacology, vol. 79, no. 7, pp. 1000–1006, 2010.
- J. Zhou, S. Zhou, J. Tang et al., “Protective effect of berberine on beta cells in streptozotocin- and high-carbohydrate/high-fat diet-induced diabetic rats,” European Journal of Pharmacology, vol. 606, no. 1–3, pp. 262–268, 2009.
- L. Liu, Y. L. Yu, J. S. Yang et al., “Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 381, no. 4, pp. 371–381, 2010.
- N. Ahmad, M. R. Hassan, H. Halder, and K. S. Bennoor, “Effect of Momordica charantia (Karolla) extracts on fasting and postprandial serum glucose levels in NIDDM patients,” Bangladesh Medical Research Council Bulletin, vol. 25, no. 1, pp. 11–13, 1999.
- E. Basch, S. Gabardi, and C. Ulbricht, “Bitter melon (Momordica Charantia): a review of efficacy and safety,” American Journal of Health-System Pharmacy, vol. 60, no. 4, pp. 356–359, 2003.
- M. J. Tan, J. M. Ye, N. Turner et al., “Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway,” Chemistry and Biology, vol. 15, no. 3, pp. 263–273, 2008.
- M. B. Krawinkel and G. B. Keding, “Bitter gourd (Momordica charantia): a dietary approach to hyperglycemia,” Nutrition Reviews, vol. 64, no. 7, pp. 331–337, 2006.
- W. D. Xie and L. J. Du, “Diabetes is an inflammatory disease: evidences fromtraditional Chinese medicines,” Diabetes, Obesity and Metabolism, vol. 13, no. 4, pp. 289–301, 2011.
- P. Khanna, S. C. Jain, A. Panagariya, and V. P. Dixit, “Hypoglycemic activity of polypeptide-p from a plant source,” Journal of Natural Products, vol. 44, no. 6, pp. 648–655, 1981.
- E. Basch, S. Gabardi, and C. Ulbricht, “Bitter melon (Momordica Charantia): a review of efficacy and safety,” American Journal of Health-System Pharmacy, vol. 60, no. 4, pp. 356–359, 2003.
- C. P. Ooi, Z. Yassin, and T. A. Hamid, “Momordica charantia for type 2 diabetes mellitus,” Cochrane Database of Systematic Reviews, vol. 2, article CD007845, 2010.
- A. Gupta, R. Gupta, and B. Lal, “Effect of Trigonella foenum-graecum (Fenugreek) seeds on glycaemic control and insulin resistance in type 2 diabetes mellitus: a double blind placebo controlled study,” Journal of Association of Physicians of India, vol. 49, pp. 1057–1061, 2001.
- D. Puri, “Fenugreek in diabetes mellitus,” The Journal of the Association of Physicians of India, vol. 47, no. 2, pp. 255–256, 1999.
- Z. Madar, R. Abel, S. Samish, and J. Arad, “Glucose-lowering effect of fenugreek in non-insulin dependent diabetics,” European Journal of Clinical Nutrition, vol. 42, no. 1, pp. 51–54, 1988.
- N. Kassaian, L. Azadbakht, B. Forghani, and M. Amini, “Effect of Fenugreek seeds on blood glucose and lipid profiles in type 2 diabetic patients,” International Journal for Vitamin and Nutrition Research, vol. 79, no. 1, pp. 34–39, 2009.
- F. R. Lu, L. Shen, Y. Qin, L. Gao, H. Li, and Y. Dai, “Clinical observation on trigonella foenum-graecum L. total saponins in combination with sulfonylureas in the treatment of type 2 diabetes mellitus,” Chinese Journal of Integrative Medicine, vol. 14, no. 1, pp. 56–60, 2008.
- R. Moorthy, K. M. Prabhu, and P. S. Murthy, “Anti-hyperglycemic compound (GII) from fenugreek (Trigonella foenum-graecum Linn.) seeds, its purification and effect in diabetes mellitus,” Indian Journal of Experimental Biology, vol. 48, pp. 1111–1118, 2010.
- T. Uemura, S. Hirai, N. Mizoguchi et al., “Diosgenin present in fenugreek improves glucose metabolism by promoting adipocyte differentiation and inhibiting inflammation in adipose tissues,” Molecular Nutrition and Food Research, vol. 54, no. 11, pp. 1596–1608, 2010.
- A. B. Singh, A. K. Tamarkar, . Shweta, T. Narender, and A. K. Srivastava, “Antihyperglycaemic effect of an unusual amino acid (4-hydroxyisoleucine) in C57BL/KsJ-db/db mice,” Natural Product Research, vol. 24, no. 3, pp. 258–265, 2010.
- F. R. Lu, L. Shen, Y. Qin, L. Gao, H. Li, and Y. Dai, “Clinical observation on trigonella foenum-graecum L. total saponins in combination with sulfonylureas in the treatment of type 2 diabetes mellitus,” Chinese Journal of Integrative Medicine, vol. 14, no. 1, pp. 56–60, 2008.
- K. Hamden, H. Masmoudi, S. Carreau, and A. Elfeki, “Immunomodulatory, β-cell, and neuroprotective actions of fenugreek oil from alloxan-induced diabetes,” Immunopharmacology and Immunotoxicology, vol. 32, no. 3, pp. 437–445, 2010.
- J. M. A. Hannan, L. Ali, B. Rokeya et al., “Soluble dietary fibre fraction of Trigonella foenum-graecum (fenugreek) seed improves glucose homeostasis in animal models of type 1 and type 2 diabetes by delaying carbohydrate digestion and absorption, and enhancing insulin action,” British Journal of Nutrition, vol. 97, no. 3, pp. 514–521, 2007.
- D. Puri, K. M. Prabhu, and P. S. Murthy, “Mechanism of action of a hypoglycemic principle isolated from fenugreek seeds,” Indian Journal of Physiology and Pharmacology, vol. 46, no. 4, pp. 457–462, 2002.
- A. M. Flammang, M. A. Cifone, G. L. Erexson, and L. F. Stankowski, “Genotoxicity testing of a fenugreek extract,” Food and Chemical Toxicology, vol. 42, no. 11, pp. 1769–1775, 2004.
- W. Abebe, “Herbal medication: potential for adverse interactions with analgesic drugs,” Journal of Clinical Pharmacy and Therapeutics, vol. 27, no. 6, pp. 391–401, 2002.
- S. Sitprija, C. Plengvidhya, V. Kangkaya, S. Bhuvapanich, and M. Tunkayoon, “Garlic and diabetes mellitus phase II clinical trial,” Journal of the Medical Association of Thailand, vol. 70, supplement 2, pp. 223–227, 1987.
- R. Ashraf, K. Aamir, A. R. Shaikh, and T. Ahmed, “Effects of garlic on dyslipidemia in patients with type 2 diabetes mellitus,” Journal of Ayub Medical College, vol. 17, no. 3, pp. 60–64, 2005.
- I. A. Sobenin, L. V. Nedosugova, L. V. Filatova, M. I. Balabolkin, T. V. Gorchakova, and A. N. Orekhov, “Metabolic effects of time-released garlic powder tablets in type 2 diabetes mellitus: the results of double-blinded placebo-controlled study,” Acta Diabetologica, vol. 45, no. 1, pp. 1–6, 2008.
- C. T. Liu, H. Hse, C. K. Lii, P. S. Chen, and L. Y. Sheen, “Effects of garlic oil and diallyl trisulfide on glycemic control in diabetic rats,” European Journal of Pharmacology, vol. 516, no. 2, pp. 165–173, 2005.
- A. Hattori, N. Yamada, T. Nishikawa, H. Fukuda, and T. Fujino, “Antidiabetic effects of ajoene in genetically diabetic KK-A mice,” Journal of Nutritional Science and Vitaminology, vol. 51, no. 5, pp. 382–384, 2005.
- K. T. Augusti and C. G. Sheela, “Antiperoxide effect of S-allyl cysteine sulfoxide, an insulin secretagogue, in diabetic rats,” Experientia, vol. 52, no. 2, pp. 115–119, 1996.
- J. J. Zhang, “Physiological function of garlic,” Zhongguo Shi Wu Yu Ying Yang, vol. 5, pp. 45–47, 2006 (Chinese).
- A. Khan, M. Safdar, M. M. A. Khan, K. N. Khattak, and R. A. Anderson, “Cinnamon improves glucose and lipids of people with type 2 diabetes,” Diabetes Care, vol. 26, no. 12, pp. 3215–3218, 2003.
- P. Crawford, “Effectiveness of cinnamon for lowering hemoglobin A1C in patients with type 2 diabetes: a randomized, controlled trial,” Journal of the American Board of Family Medicine, vol. 22, no. 5, pp. 507–512, 2009.
- P. Anand, K. Y. Murali, V. Tandon, P. S. Murthy, and R. Chandra, “Insulinotropic effect of cinnamaldehyde on transcriptional regulation of pyruvate kinase, phosphoenolpyruvate carboxykinase, and GLUT4 translocation in experimental diabetic rats,” Chemico-Biological Interactions, vol. 186, no. 1, pp. 72–81, 2010.
- W. Kim, L. Y. Khil, R. Clark, S. H. Bok, E. E. Kim, and S. Lee, “Naphthalenemethyl ester derivative of dihydroxyhydrocinnamic acid, a component of cinnamon, increases glucose disposal by enhancing translocation of glucose transporter 4,” Diabetologia, vol. 49, no. 10, pp. 2437–2448, 2006.
- J. Imparl-Radosevich, S. Deas, M. M. Polansky et al., “Regulation of PTP-1 and insulin receptor kinase by fractions from cinnamon: implications for cinnamon regulation of insulin signalling,” Hormone Research, vol. 50, no. 3, pp. 177–182, 1998.
- J. J. Dugoua, D. Seely, D. Perri et al., “From type 2 diabetes to antioxidant activity: a systematic review of the safety and efficacy of common and cassia cinnamon bark,” Canadian Journal of Physiology and Pharmacology, vol. 85, no. 9, pp. 837–847, 2007.
- Z. C. Li, J. X. Shi, Q. R. Li, and S. J. Dai, “Clinical effect of Yu-quan pills in treatment of 18 diabetic patients,” Zhong Cheng Yao, vol. 2, pp. 17–18, 1984 (Chinese).
- Y. Zheng and D. Q. Huang, “Effects of Yuquan Wan on the index of kidney injure of early diabetic nephropathy,” Xia Dai Zhong Yao Yan Jiu Yu Shi Jian, vol. 19, pp. 42–44, 2005 (Chinese).
- C. Peng and C. H. Zheng, “Effect of Yuquan Wan on insulin sentivity in patients with type 2 diabetes,” Hubei Zhong Yi Zha Zhi, vol. 30, pp. 11–12, 2008 (Chinese).
- Y. Q. Deng, X. F. Fan, and G. L. Wu, “Effect of yuquan pill on proinflammatory cytokines in patients with type 2 diabetes mellitus,” Zhongguo Zhong xi yi jie he za zhi, vol. 26, no. 8, pp. 706–709, 2006 (Chinese).
- H. G. Duan, Y. H. Wei, B. X. Li, D. M. Zhang, J. W. Zhang, and X. A. Wu, “Effects of Yuquan pills on pharmacokinetics of metformin hydrochloride in diabetic rats,” Zhongguo Zhongyao Zazhi, vol. 33, no. 18, pp. 2133–2139, 2008 (Chinese).
- L. Liu, “Observation of the effects of Zhong-Hui Tangmaikang Jiaonang in treatment of 60 patients of type 2 diabetes,” Shanghai Yi Yao, vol. 21, pp. 21–23, 2000 (Chinese).
- M. Zhang, H. H. Yu, and X. P. Ding, “Observations of the effects of Zhong-Hui Tangmaikang in treatment of 30 cases of type 2 diabetic patients,” Gansu Zhong Yi, vol. 2, p. 21, 2001 (Chinese).
- X. Li, W. H. Gao, and Y. P. Wu, “Influence of Tangmaikang Jiaonang in insulin resistance in type 2 diabetic patients,” Hebei Zhong Yi, vol. 26, pp. 180–181, 2004 (Chinese).
- Y. F. Zhang, “Observation of curative effect of Kelening in type 2 diabetic patients with sulfonylurea failure,” Yi Nan Bing Za Zhi, vol. 3, pp. 25–26, 2004 (Chinese).
- Q. A. Zhang, H. P. Wang, and X. B. Liu, “Influence of Tangmaikang gralnule in blood lipids in senile diabetic patiens,” Yi Yao Dao Bao, vol. 19, p. 162, 2000 (Chinese).
- X. Y. Li, “Investigation into the effects of Tangmaikang Jiaonang in treatment of diabetic peripheral nepheropathy,” Chengdu Zhong Yi Yao Da Xue Xue Bao, vol. 28, pp. 46–47, 2005 (Chinese).
- B. Lin, “Tangmaikang in treatment of 60 patients of NIDDM,” Jilin Zhong Yi Yao, vol. 1, p. 31, 1999 (Chinese).
- Z. G. Chen and R. Chen, “The clinical observation of 68 cases of type 2 diabetic mellitus treated by Taimaikang Granule,” Zhongguo Yi Yao Dao Kan, vol. 12, no. 5, pp. 787–788, 2010 (Chinese).
- W. Du, J. Z. Guo, and J. Jin, “Observations of effects of Tangmaikang combined with metformin in treatment of newly diagnosed type 2 diabetes,” Ningxia Yi Ke Da Xue Xue Bao, vol. 32, pp. 93–94, 2010 (Chinese).
- Y. Zhang, L. X. Cheng, H. X. Liu, H. Y. Li, and X. F. Meng, “Clinical observations of Tangmaikang Keli in treatment of diabetic peripheral neuropathy,” Zhongguo Dang Dai Yi Yao, vol. 17, pp. 97–98, 2010 (Chinese).
- J. T. Zhou, T. H. Lin, and Z. Z. Zhou, “Clinical observations of Tangmaikang in treatment of 60 cases of type 2 diabetic patients,” Zhongguo Shi Yong Yi Yao, vol. 4, pp. 107–108, 2009 (Chinese).
- R. Zhou, J. J. Guo, C. M. Yin, and T. K. Li, “Clinical observations of Xiaoke Wan in treatment of type 2 diabetic patients (Qi and Yin deficiency zheng),” Zhongguo Yao Wu Yu Lin Chuang, vol. 3, pp. 131–132, 2003 (Chinese).
- H. Z. Zhang, “Clinical observation into Xiaoke Wan in the treatment of 86 cases of type 2 diabetic patients,” Zhong Yi Yao Yan Jiu, vol. 15, pp. 19–21, 1999 (Chinese).
- Y. C. Zhao and M. Hou, “Xiaoke Wan in treatment of 200 cases of type 2 diabetic patients,” Changchun Zhong Yi Xue Yuan Xue Bao, vol. 14, p. 15, 1998 (Chinese).
- G. Chen, Y. D. Ni, X. M. Lai, and H. Q. Liang, “Clinical study on Xiaoke Wan in treating type 2 diabetes mellitus with Qi and Yin Defiency,” Zhong Yao Xin Yao Yu Lin Chuang Yao Li, vol. 14, no. 2, pp. 84–86, 2003 (Chinese).
- J. L. Wu, “Observations into the effects of Xiaoke Wan in treatment of diabetes,” Shi Yong Zhong Xi Yi Jie He Lin Chuang, vol. 5, pp. 18–19, 2005 (Chinese).
- S. Li, “Effects of Xiaoke Wan on serum adiponectin levels in patients with type 2 diabetes mellitus,” International Journal of Traditional Chinese Medicine, vol. 32, no. 2, pp. 112–114, 2010 (Chinese).
- Y. Qu and L. Zhang, “Analysis of 36 severe low blood sugar reactions of Xiaokewan,” Zhongguo Yao Wu Jing Jie, vol. 6, pp. 99–101, 2009 (Chinese).
- N. Zhou and B. K. Peng, “Clinical effect evaluation of Jinqi Jiangtang Pian in treatment of type 2 diabetic patients,” Yunnan Zhong Yi Zhong Yao Za Zhi, vol. 20, p. 15, 1999 (Chinese).
- W. Y. Gu, “Clinical observation of Jinqi Jiangtang Pian combined with glibenclamide in treatment of type 2 diabetic patients,” Tianjin Yi Ke Da Xue Xue Bao, vol. 10, pp. 87–89, 2004 (Chinese).
- P. L. Shen, “Hypoglycemic and lipid-regulating effects of Jinqi Jiangtang Pian in type 2 diabetic patients,” Tianjin Yi Yao, vol. 33, p. 803, 2005 (Chinese).
- S. J. Ma, Y. H. LV, D. Chen, and Z. W. Wang, “Protective effects of Jinqi Jiangtang Pians in the kidney in the early stage of diabetic nephropathy,” Sichuang Zhong Yi, vol. 22, pp. 39–40, 2004 (Chinese).
- H. Y. Qian, “Clinical observations of effects of Jinqi Jiantang Pian in treatment of type 2 diabetes,” Jlin Yi Xue, vol. 31, p. 2212, 2010 (Chinese).
- H. Cao, M. Ren, L. Guo et al., “JinQi-Jiangtang tablet, a Chinese patent medicine, for pre-diabetes: a randomized controlled trial,” Trials, vol. 11, article 27, 2010.
- Z. F. Shen, “Pharmacological basis on anti-diabetic activities of Jinqi Jiangtang Pian,” Guo Wai Yi Xue, vol. 24, no. 3, pp. 215–216, 2004 (Chinese).
- X. Y. Lai, “Observation into the therapeutic effects of Jiangtangjia Pian in treatment of 48 cases of type 2 diabetic patients,” Jiangxi Zhong Yi Yao, vol. 30, p. 50, 1999 (Chinese).
- Y. L. Liu and C. S. Li, “Kelening in treatment of 30 cases of type 2 diabetic patients with Qi and Yin deficiency,” Shandong Zhong Yi Za Zhi, vol. 15, pp. 302–303, 1996 (Chinese).
- P. Zhou, “Clinical study of glibenclamide in combination with kelening treatment in type 2 diabetic patients,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 17, pp. 29–31, 1997 (Chinese).
- H. J. Yang, L. Yao, and J. F. Hua, “Kelening in management of 30 cases of NIDDM,” Shanghai Zhong Yi Yao Za Zhi, vol. 9, p. 13, 1997 (Chinese).
- C. Zhang, “Tangmaikang in treatment of insulin resistance in 26 diabetic patients,” Jiang Su Zhong Yi Yao, vol. 25, p. 44, 2004 (Chinese).
- B. R. Gong, Z. P. He, Y. S. Fang, and L. Y. Zhu, “Pharmacodynamics effects of Jiangtangjia Pian,” Shi Yan Dong Wu Ke Xue Yu Guan Li, vol. 19, no. 2, pp. 45–46, 2002 (Chinese).
- Y. P. Yang and W. Z. Huang, “Drug efficacy study of Thirst Reliever capsule,” Xian Dai Zhong Xi Yi Jie He Zha Zhi, vol. 16, pp. 2826–2827, 2007 (Chinese).
- L. M. Fang, T. W. Zhang, H. J. Zhuang, and H. Li, “Clinical observation on Xiaotangling in treatment of type 2 diabetic patients,” Guiyang Yi Xue Yuan Xue Bao, vol. 28, pp. 337–338, 2003 (Chinese).
- J. X. Liu, “44 cases of diabetes mellitus with Qi, Yin deficiency and Yu treated with Xiaotangling Jiaonang,” Zhongguo Yao Ye, vol. 14, no. 9, p. 79, 2005 (Chinese).
- Z. M. Lu, Q. H. Cao, Y. L. Yang, and W. H. Jia, “Clinical observation on Xiaotangling Jiaonang combined with dimethyldiguanide in treating 150 cases of type 2 diabetes mellitus,” Hebei Zhong Yi, vol. 24, pp. 563–565, 2002 (Chinese).
- Y. S. Wang, X. H. Su, W. D. Li, X. Y. Wang, F. S. Tian, and Y. X. Li, “Clinical and experimental studies on Xiaotangling Jiaonangs in insulin resistance of type 2 diabetes mellitus,” Zhongguo Zhong Yi Yao Xing Xi Za Zhi, vol. 10, pp. 17–19, 2003.
- G. Sun, Z. L. Hu, and Z. Z. Lin, “Clinical observation on 35 cases of type 2 diabetic patients treated with Shenqi Jiangtang Keli,” Fujian Zhong Yi Xue Yuan Xue Bao, vol. 9, pp. 14–15, 1999 (Chinese).
- Z. D. Ye and J. J. Wu, “Analysis of therapeutic effect on type 2 diabetes mellitus treated by Shenqi Jiangtang Granule,” Zhongguo Shi Yong Nei Ke Zha Zhi, vol. 25, pp. 788–789, 2009 (Chinese).
- H. C. Gu, “Clinical observation of Shenqi Jiangtang Keli in treatment of 235 cases of type 2 diabetes,” Shandong Yi Yao, vol. 48, p. 116, 2008 (Chinese).
- Z. X. Yu, “Evaluation of efficacy of Shenqi Jiangtang Keli in 38 Cases of diabetic patients with secondary-failure to sulfonylureas,” Gong Qi Yi Kan, vol. 16, no. 5, pp. 3–4, 2003 (Chinese).
- X. L. Zhou and Y. Y. Sun, “Evaluation of actions of Shenqi Jiangtang Keli on glucose tolerance and pancreatic beta-islet function in patients,” Zhongguo Zhong Yi Ji Zheng, vol. 15, no. 4, pp. 369–370, 2006 (Chinese).
- R. W. Zhan, “Curative observation on 120 cases of type 2 diabetes mellitus in treatment of Yangyin Jiangtang Pian in combination with metformin,” Hebei Zhong Yi, vol. 26, pp. 748–749, 2004 (Chinese).
- P. Huang, M. H. Yang, W. Z. Gu, X. C. Yang, and G. M. Shao, “Experimental study on diabetic rat with hyperviscosity sysdrome treated with Yangyinjiangtang Tablet,” Zhongguo Zhong Yi Ke Ji, vol. 8, no. 6, pp. 349–351, 2001.
- D. P. Lei and Y. Q. Li, “Clinical and experimental studies of Xiaoke Jiangtang Pian in treatment of diabetes mellitus,” Zhong Cheng Yao, vol. 11, p. 2, 1988 (Chinese).
- G. T. Yin and R. H. Cui, “Yijin jiangtang capsules for treatment of 42 patients with diabetes type II,” Xinxiang Yi Xue Yuan Xue Bao, vol. 20, pp. 372–374, 2003 (Chinese).
- Y. J. Li and H. X. Xu, “Research progress on anti-diabetic Chinese Medicines,” Zhong Yao Cai, vol. 29, pp. 621–625, 2009.
- J. Li, “Thinking on syndrome differentiation treatment and personalized therapy for tumor,” Journal of Chinese Integrative Medicine, vol. 7, no. 4, pp. 306–308, 2009.